Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided
clinical, operational, and data management support to ADNI since its inception. This article …

In 2018, there was a recent shift towards a biological definition of Alzheimer's disease (AD),
based on biomarkers measured in vivo even before the onset of clinical dementia …

Abstract Purpose of Review: This article reviews recent advances in imaging and fluid
biomarkers for Alzheimer disease (AD) and their application to newly proposed diagnostic …

In this study, we review progress by the Penn Biomarker Core in the Alzheimer's Disease
Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) …

BACKGROUND: The Alzheimer's Disease Neuroimaging Initiative Phase 1 (ADNI-1) is a
multisite prospective study designed to examine potential cerebrospinal fluid and imaging …

Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The
prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy …

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

With the increasing life expectancy in developed countries, the incidence of Alzheimer's
disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over …